Effects of chemical carcinogens on the susceptibility of C57BL/10 and (SJL/J x C57BL/10) F/sub 1/ hybrids to Friend leukemia virus [electronic resource].
- Oak Ridge, Tenn. : Distributed by the Office of Scientific and Technical Information, U.S. Dept. of Energy, 1980.
- Physical Description:
- Pages: 13 : digital, PDF file
- Additional Creators:
- United States. Department of Energy. Office of Scientific and Technical Information
- Under normal circumstances cells of C57BL/10 mice are resistant to infection by Friend leukemia virus (FLV). Pre-treatment by chemical carcinogens does not affect the susceptibility of C57BL/10 mice to FLV leukemogenesis. However, immunosuppression by cyclophosphamide or a congenitally athymic condition allows the replication of the LLV component of FLV to take place in these mice. F1 hybrids between C57BL/10 and SJL/J mice are also resistant to virus, although about twenty percent of these hybrids develop leukemia after massive doses of FLV. Unexpectedly, the F1 hybrid with the virus-sensitive SJL/J mother was more resistant than the F1 hybrid from the reciprocal cross. Pre-treatment of the F1 hybrid or SJL/J mice with chemical carcinogens, such as methyl methane sulfonate and benzo(a)pyrene, but not cyclophosphamide, increased the incidence of leukemia with a peak of increased susceptibility developing at a specific time after treatment. A chemical carcinogen-caused depression of the viability of hematopoietic cells in the spleen, which cells are the major target for FLV oncogenesis, was also temporally related with the increase in susceptibility to the virus. Our data correlated with information on the alleles known to affect resistance to murine leukemia viruses.
- Published through SciTech Connect., 01/01/1980., "coo-4800-8", " conf-800378-1", Genetic control of natural resistance to infection and malignancy, Montreal, Canada, 18 Mar 1980., OKunewick, J.P.; Raikow, R.B.; Brozovich, B.J.; Seeman, P.R.; Magliere, K.C., and Allegheny-Singer Research Corp., Pittsburgh, PA (USA). Cancer Research Labs.
- Funding Information:
View MARC record | catkey: 14794320